Since April 11, 2025, UnitedHealth Group (NYSE: UNH) has undergone a prolonged and concerning decrease, culminating in a sharp 5.71% drop on May 21, finishing at $302.98. This represents one of the steepest daily selloffs in the stock’s history and brings UNH to levels not seen in five years. The extended slump, prompted by disappointing Q1 results, reduced full-year guidance, and growing operational concerns, has now erased 42% of the stock’s value year-to-date and 43% over the last 12 months. In this thorough assessment, we investigate whether one should Buy or Fear UnitedHealth stock.
This significant decline is noteworthy even within a difficult healthcare landscape when viewed in comparison with some of its competitors. Cigna has demonstrated unexpected resilience, increasing by 4% in 2025 and 5.8% over the previous year. Molina Healthcare is also holding strong, with a 2.4% increase year-to-date and a slight annual decline of 3%. At the same time, CVS Health and Centene have exhibited relative stability. The only outlier is Humana, which, like UnitedHealth, has experienced a substantial drop of over 45%, primarily due to pressures on Medicare Advantage. In this peer comparison, UnitedHealth’s correction appears both sector-driven and significantly more pronounced.
Valuation: A Compelling Discount
In spite of the market’s adverse response, UnitedHealth seems attractively priced compared to the broader market. The stock is trading at a price-to-sales ratio of just 0.7, significantly lower than the S&P 500’s 2.8. Its price-to-earnings ratio is at 12.4, well beneath the S&P’s 24.5, and its price-to-free cash flow ratio is 9.6, in contrast to 17.6 for the index. This notable valuation discount indicates that much of the operational risk may already be incorporated into the price, presenting long-term investors a potential entry opportunity.
Growth: Strong and Steady Momentum
In terms of revenue, UnitedHealth continues to exhibit solid growth. The company’s top line has expanded at an average annual rate of 11.3% over the last three years. In the past 12 months alone, revenue increased 8.1% from $372 billion to $400 billion. The latest quarter further highlighted this trend, with revenue rising 9.8% year-over-year to $101 billion. These numbers demonstrate the company’s capacity to sustain growth while facing considerable market challenges.
Profitability: A Noticeable Weak Spot
Where UnitedHealth continues to fall short is in profitability. Over the previous four quarters, the company achieved operating income of $33 billion, translating to a modest operating margin of 8.2%. Net income was recorded at $22 billion, resulting in a net margin of just 5.4%, while operating cash flow amounted to $29 billion, corresponding to a 7.0% OCF margin. These margins indicate that UnitedHealth is not effectively converting its revenue scale into margin efficiency, a concern obscuring its earnings outlook.
Financial Stability: Neutral but Balanced
Despite the profit pressures, UnitedHealth’s balance sheet remains robust. As of the latest quarter, the company had $81 billion in debt against a market capitalization of $378 billion (as of April 30, 2025), leading to a debt-to-equity ratio of 29.6%—a moderate level. With $29 billion in cash and equivalents, which represents 11.1% of total assets, UnitedHealth sustains strong liquidity and the financial flexibility to navigate near-term disruptions.
Downturn Resilience: A Proven Performer in Crisis
One of UnitedHealth’s more enduring strengths is its resilience during past market downturns. During the 2022 inflation shock, the stock fell 19.3%, which is less than the S&P 500’s 25.4%, and it rebounded to its pre-crisis peak by July 2024, achieving a post-crisis high of $625.25 before its current decline. During the COVID-19 crash in 2020, UNH decreased by 36.2% but recovered to previous highs by June 2020. Even amid the 2008 financial crisis, when the stock plummeted 72.4%, it managed to fully bounce back by April 2012. This history underscores UnitedHealth’s capability to endure systemic shocks better than many competitors.
Conclusion: Risks Remain, but the Value Is Hard to Ignore
Although UnitedHealth’s sharp stock decline and profitability issues are legitimate concerns, its ongoing revenue growth, solid balance sheet, and historical resilience imply that the selloff may be excessive. The company’s deep valuation discount relative to the broader market provides an additional layer of downside protection for long-term investors. As management focuses on restoring operational efficiency, the stock may present a compelling recovery narrative for those prepared to weather the storm.
Investing in a single stock like UNH can be risky. Conversely, the Trefis High Quality (HQ) Portfolio, which comprises 30 stocks, has a history of comfortably outperforming the S&P 500 over the past four years. Why is that? As a group, HQ Portfolio stocks delivered superior returns with lower risk compared to the benchmark index, creating less of a turbulent experience as reflected in HQ Portfolio performance metrics.